
    
      Primary Objective: To assess the safety of the study drug for patients prescribed with the
      study drug under the approved indications in South Korea Secondary Objective: To assess
      effectiveness of the study drug for patients prescribed with the study drug under the
      approved indication in South Korea Exploratory Objective: To assess effectiveness of the
      study drug for ovarian cancer patients diagnosed as Homologous Recombination Deficiency (HRD)
      positive via locally available validated HRD test and prescribed with the study drug under
      the approved indication in South Korea
    
  